Long-Term Respiratory Muscle Strength in Young COVID-19 Patients

Karabuk University

Status: Completed

Conditions: COVID-19

Study type: Observational

Funder types: Other

Identifiers

NCT05381714

POST-COVID

Details and patient eligibility

About

The coronavirus disease 2019 (COVID-19) is a highly contagious disorder caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 is a multisystem disease and therefore presents a variety of symptoms in the acute phase, such as fever, dry cough, fatigue, sore throat, loss of taste or smell, shortness of breath, nasal congestion, chest pain, muscle or joint pain, headache, and nausea.

COVID-19 primarily affects the respiratory functions of individuals. Although this situation is more difficult in hospitalized patients, it also causes severe effects in individuals who recover with home medication. It is thought that this damage caused by COVID-19 may cause permanent effects on individuals in the long term. During the COVID-19 period, individuals also had to maintain an inactive lifestyle due to quarantine. This decrease in physical activity capacity also causes permanent damage to the respiratory functions of individuals. In addition, studies have focused on this population, as COVID-19 usually affects older individuals. However, considering that young people are also exposed to the COVID-19 virus, the effect on respiratory functions in these individuals should also be examined. Combined with the available information on pulmonary functions, there is insufficient evidence about extrapulmonary features in post-COVID-19 patients who survive mild illness in the long term. It is also necessary to examine whether there is permanent damage to extrapulmonary features such as peripheral muscle strength in these individuals.

Therefore, in our study, it is aimed to examine the long-term results of respiratory functions, respiratory muscle strength and peripheral muscle strength of young individuals who recovered from COVID-19 and recovered from mild disease.

Enrollment: 100 patients

Sex: All

Ages: 18 to 25 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Patients:

• diagnosed with COVID-19, with a positive polymerase chain reaction (PCR) test
• at least six months ago (long term)
• non-hospitalization due to COVID-19
• non-smoker / for ex-smokers with 10 pack x years or less of smoking
• not continuing any regular physical activity program

Controls:

• non-smoker / for ex-smokers with 10 pack x years or less of smoking,
• not continuing any regular physical activity program
• willing to participate to the study

Exclusion criteria

• receiving inpatient or intensive care treatment due to COVID-19
• having acute infection
• previous pulmonary resection or cardiac surgery
• having lung or heart comorbidities such as asthma
• chronic obstructive pulmonary disease (COPD) and heart failure
• uncontrolled hypertension
• history of malignancy
• neurological disease (e.g., Alzheimer, Multiple Sclerosis, Parkinson)
• rheumatologic diseases

Trial design

100 participants in 2 patient groups

Patients

Description:

Post-COVID-19 Functional Status (Post-COVID-19 Functional Status Scale), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), physical activity level (International Physical Activity Questionnaire), fatigue (Modified Borg Scale), shortness of breath (Modified Borg Scale) will be evaluated.

Control

Description:

Respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), physical activity level (International Physical Activity Questionnaire), fatigue (Modified Borg Scale), shortness of breath (Modified Borg Scale) will be evaluated.